Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study-Reference-Cited by-同舟云学术

Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study

Published:2020-02 Issue:1 Volume:53 Page:60-68
ISSN:1684-1182
Container-title:Journal of Microbiology, Immunology and Infection
language:en
Short-container-title:Journal of Microbiology, Immunology and Infection

Author:

Huang Sung-Hsi,Lin Shu-Wen,Chang Sui-Yuan,Lin Ya-Ting,Sun Hsin-Yun,Liu Wen-Chun,Su Yi-Ching,Hung Chien-Ching,Chang Shan-Chwen

Funder

National Taiwan University Hospital

Centers for Disease Control, Taiwan

Taiwan Centers for Disease Control

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,General Medicine,Immunology and Allergy

Reference31 articles.

1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection;World Health Organization,2016

2. Combined global demand forecasts for antiretroviral medicines and HIV diagnostics in low-and middle-income countries from 2015 to 2020;World Health Organization,2016

3. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan;Wu;PLoS One,2017

4. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring;Gutiérrez;Clin Infect Dis,2005

5. Plasma efavirenz concentrations are associated with lipid and glucose concentrations;Sinxadi;Medicine,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia;CPT: Pharmacometrics & Systems Pharmacology;2023-03-23

2. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;J MICROBIOL IMMUNOL;2021

3. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;Journal of Microbiology, Immunology and Infection;2021-10

4. Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV;JAIDS Journal of Acquired Immune Deficiency Syndromes;2021-06-01

5. Implementation and outcomes of a therapeutic drug monitoring program for antifungal and antiretroviral agents in a tertiary medical center in Taiwan;Journal of the American College of Clinical Pharmacy;2020-07-09